


What is claimed is:

1. ~~A compound of Formula (I'):~~



or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

5 ring A is azetidiny, pyrrolidinyl or piperidinyl;

~~X¹ is CH or N;~~

~~R¹ is methyl or halo;~~

~~R² is C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-haloalkyl, C₁₋₄-haloalkoxy, C₃₋₆-cycloalkyl, C₃₋₆-cycloalkyl-C₁₋₂-alkyl, OH, NH₂, NH-C₁₋₄-alkyl, N(C₁₋₄-alkyl)₂, 4 to 6-membered~~

10 heterocycloalkyl or 4 to 6-membered heterocycloalkyl-C₁₋₂-alkyl, wherein the 4 to 6-membered heterocycloalkyl and 4 to 6-membered heterocycloalkyl-C₁₋₂-alkyl each has one or two heteroatoms as ring members selected from O and N, and wherein the C₁₋₄-alkyl, C₁₋₄-alkoxy, C₃₋₆-cycloalkyl, C₃₋₆-cycloalkyl-C₁₋₂-alkyl, NH-C₁₋₄-alkyl, N(C₁₋₄-alkyl)₂, 4 to 6-membered heterocycloalkyl and 4 to 6-membered heterocycloalkyl-C₁₋₂-alkyl of R² are each


15 optionally substituted with 1 or 2 substituents independently selected from halo, CN and OH;

~~R³ is selected from (R)-3-hydroxy-3-methylpyrrolidin-1-yl, (S)-3-hydroxy-3-methylpyrrolidin-1-yl, (R)-3-hydroxypyrrolidin-1-yl, (S)-3-hydroxypyrrolidin-1-yl, (R)-2-hydroxy-2-methyl-ethylamino, (S)-2-hydroxy-2-methyl-ethylamino, (R)-2-hydroxy-1-methyl-ethylamino and (S)-2-hydroxy-1-methyl-ethylamino; and~~

20 R⁴ is H or C₁₋₃-alkyl; and

~~R⁵ is C(O)OH, C(O)N(CH₃)₂, C(O)NH(CH₃), or C(O)NH(CH₂)₂C(O)OH.~~

2. ~~A compound of Formula (I):~~



25 or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:

ring A is azetidiny, pyrrolidinyl or piperidinyl;

X¹ is CH or N;

R¹ is methyl or halo;

R² is C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-haloalkyl, C₁₋₄-haloalkoxy, C₃₋₆-cycloalkyl, C₃₋₆

5 cycloalkyl-C₁₋₂-alkyl, OH, NH₂, NH-C₁₋₄-alkyl, N(C₁₋₄-alkyl)₂, 4 to 6-membered heterocycloalkyl or 4 to 6-membered heterocycloalkyl-C₁₋₂-alkyl, wherein the 4 to 6-membered heterocycloalkyl and 4 to 6-membered heterocycloalkyl-C₁₋₂-alkyl each has one or two heteroatoms as ring members selected from O and N, and wherein the C₁₋₄-alkyl, C₁₋₄-alkoxy, C₃₋₆-cycloalkyl, C₃₋₆-cycloalkyl-C₁₋₂-alkyl, NH-C₁₋₄-alkyl, N(C₁₋₄-alkyl)₂, 4 to 6-membered heterocycloalkyl and 4 to 6-membered heterocycloalkyl-C₁₋₂-alkyl of R² are each optionally substituted with 1 or 2 substituents independently selected from halo, CN and OH;


R³ is selected from (R)-3-hydroxy-3-methylpyrrolidin-1-yl, (S)-3-hydroxy-3-methylpyrrolidin-1-yl, (R)-3-hydroxypyrrolidin-1-yl, (S)-3-hydroxypyrrolidin-1-yl, (R)-2-hydroxy-2-methyl-ethylamino, (S)-2-hydroxy-2-methyl-ethylamino, (R)-2-hydroxy-1-methyl-ethylamino and (S)-2-hydroxy-1-methyl-ethylamino; and

R⁴ is H or C₁₋₃-alkyl.

3.—The compound of claim 1 or 2, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein ring A is pyrrolidinyl.


4.—The compound of claim 1 or 2, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein ring A is piperidinyl.

5.—The compound of claim 1 or 2, or a pharmaceutically acceptable salt or a



25 stereoisomer thereof, wherein is selected from 4-carboxypiperidin-1-yl, 3-carboxypyrrolidin-1-yl, 3-methyl-3-carboxypyrrolidin-1-yl, 4-(N,N-dimethylaminocarbonyl)piperidin-1-yl, 4-(N-methylaminocarbonyl)piperidin-1-yl, and 4-(2-carboxyethylaminocarbonyl)piperidin-1-yl, wherein the wavy line indicates the point of attachment to the rest of the molecule.


6. — The compound of claim 1 or 2, or a pharmaceutically acceptable salt or a



stereoisomer thereof, wherein is selected from 4-carboxypiperidin-1-yl, 3-carboxypyrrolidin-1-yl, and 3-methyl-3-carboxypyrrolidin-1-yl, wherein the wavy line indicates the point of attachment to the rest of the molecule.

5

7. — The compound of claim 1 or 2, or a pharmaceutically acceptable salt or a



stereoisomer thereof, wherein is selected from 4-carboxypiperidin-1-yl, (R)-3-carboxypyrrolidin-1-yl, (S)-3-carboxypyrrolidin-1-yl, (R)-3-methyl-3-carboxypyrrolidin-1-yl and (S)-3-methyl-3-carboxypyrrolidin-1-yl, wherein the wavy line indicates the point of attachment to the rest of the molecule.

10

8. — The compound of any one of claims 1-7, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein X^1 is N.

15

9. — The compound of any one of claims 1-7, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein X^1 is CH.

10. — The compound of any one of claims 1-9, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^1 is CH₃ or Cl.

20

11. — The compound of any one of claims 1-9, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^1 is CH₃.

25

12. — The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^2 is C₁₋₄-alkyl, C₁₋₄-alkoxy, C₁₋₄-haloalkyl, C₁₋₄-haloalkoxy, C₃₋₆-cycloalkyl, C₃₋₆-cycloalkyl-C₁₋₂-alkyl, OH, NH₂, NH-C₁₋₄-alkyl, N(C₁₋₄-alkyl)₂, 1-azetidiny, azetidin-1-ylmethyl, 1-pyrrolidinyl, pyrrolidin-1-ylmethyl, 1-piperidinyl, or piperidin-1-ylmethyl, wherein the C₁₋₄-alkyl, C₁₋₄-alkoxy, C₃₋₆-cycloalkyl, C₃₋₆-cycloalkyl-C₁₋₂-alkyl, NH-C₁₋₄-alkyl, N(C₁₋₄-alkyl)₂, 1-azetidiny, azetidin-1-ylmethyl, 1-pyrrolidinyl, pyrrolidin-1-

ylmethyl, 1-piperidinyl and piperidin-1-ylmethyl of R^2 are each optionally substituted with 1 or 2 substituents independently selected from halo, CN and OH.

13. — The compound of claim 12, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^2 is methyl, ethyl, isopropyl, methoxy, ethoxy, CF_3 , CHF_2 , CFH_2 , OCF_3 , $OCHF_2$, OCH_2F , cyclopropyl, cyclobutyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl, OH, NH_2 , $NHCH_3$, $N(CH_3)_2$, 1-azetidiny, azetidin-1-ylmethyl, 1-pyrrolidinyl, pyrrolidin-1-ylmethyl, 1-piperidinyl or piperidin-1-ylmethyl, wherein the methyl, ethyl, isopropyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl, $NHCH_3$, $N(CH_3)_2$, 1-azetidiny, azetidin-1-ylmethyl, 1-pyrrolidinyl, pyrrolidin-1-ylmethyl, 1-piperidinyl and piperidin-1-ylmethyl of R^2 are each optionally substituted with 1 or 2 substituents independently selected from F, Cl, Br, CN and OH.

14. — The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^2 is C_{1-4} -alkyl or C_{1-4} -haloalkyl, each of which is optionally substituted with 1 or 2 substituents independently selected from F, Cl, Br, CN and OH.

15. — The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^2 is C_{1-4} -alkyl or C_{1-4} -haloalkyl.

16. — The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^2 is CH_3 , CF_3 , CHF_2 , $CH(CH_3)_2$, NH_2 , cyclopropyl, or CH_2OH .

17. — The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^2 is CH_3 , CF_3 , CHF_2 or $CH(CH_3)_2$.

18. — The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^2 is CH_3 .

19. — The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^2 is CF_3 or CHF_2 .

~~20. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^2 is $CH(CH_3)_2$.~~

~~21. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^2 is NH_2 .~~

~~22. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^2 is cyclopropyl.~~

~~23. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^2 is CH_2OH .~~

~~24. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^3 is (R)-3-hydroxy-3-methylpyrrolidin-1-yl or (S)-3-hydroxy-3-methylpyrrolidin-1-yl.~~

~~25. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^3 is (R)-3-hydroxypyrrolidin-1-yl or (S)-3-hydroxypyrrolidin-1-yl.~~

~~26. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^3 is (R)-2-hydroxy-2-methyl-ethylamino or (S)-2-hydroxy-2-methyl-ethylamino.~~


~~27. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^3 is (R)-2-hydroxy-1-methyl-ethylamino or (S)-2-hydroxy-1-methyl-ethylamino.~~

~~28. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^4 is H or CH_3 .~~

~~29. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R^4 is H.~~


~~30. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R⁴ is CH₃.~~

~~31. The compound of claim 1 having Formula II:~~




~~or a pharmaceutically acceptable salt or a stereoisomer thereof.~~

~~32. The compound of claim 1 having Formula III:~~




~~or a pharmaceutically acceptable salt or a stereoisomer thereof.~~

~~33. The compound of claim 1 having Formula IV:~~



~~or a pharmaceutically acceptable salt or a stereoisomer thereof.~~

~~34. The compound of claim 1 having Formula V:~~



~~or a pharmaceutically acceptable salt or a stereoisomer thereof.~~

5 ~~351. The A compound of claim 1, wherein the compound is selected from: which is~~

~~(R)-1-((7-cyano-2-(3'-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;~~

~~(R)-1-((7-cyano-2-(3'-(7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;~~

~~(S)-1-((7-cyano-2-(3'-(7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;~~

~~(S)-1-((7-cyano-2-(3'-(7-((1-hydroxypropan-2-ylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;~~

~~(S)-1-((7-cyano-2-(3'-(7-((2-hydroxypropylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;~~

~~(R)-1-((7-cyano-2-(3'-(7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;~~

~~(R)-1-((7-cyano-2-(3'-(7-(((R)-3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;~~

~~(R)-1-((7-cyano-2-(3'-(7-(((S)-3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;~~

~~(R)-1-((7-cyano-2-(3'-(7-(((S)-1-hydroxypropan-2-ylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;~~

~~(R)-1-((7-cyano-2-(3'-(7-(((S)-2-hydroxypropylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;~~

~~(R)-1-((7-cyano-2-(3'-(7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid;~~

~~(R)-1-((7-cyano-2-(3'-(7-(((R)-3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid;~~

~~(R)-1-((7-cyano-2-(3'-(7-(((S)-3-hydroxy-3-methylpyrrolidin-1-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid;~~

~~(R)-1-((7-cyano-2-(3'-(7-(((S)-1-hydroxypropan-2-ylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid;~~

~~(R)-1-((7-cyano-2-(3'-(7-(((S)-2-hydroxypropylamino)methyl)-2-methylpyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid;~~

~~(R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;~~

~~(R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;~~

~~(R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid;~~

~~(R)-1-((7-cyano-2-(3'-(7-((3-hydroxypyrrolidin-1-yl)methyl)-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;~~

(R)-1-((7-cyano-2-(3'-(7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid; and

(R)-1-((7-cyano-2-(3'-(7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-2-(trifluoromethyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

2. The compound of claim 1, which is (R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid.

36.—The compound of claim 1, wherein the compound is selected from:

(S)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;

(S)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid;

(R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-4-methylpiperidine-4-carboxylic acid;

(R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-N,N-dimethylpiperidine-4-carboxamide;

(R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-N-methylpiperidine-4-carboxamide;

(R)-3-(1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxamido)propanoic acid;

(R)-1-((7-cyano-2-(3'-(2-cyclopropyl-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;

~~(R)-1-((2-(3'-(2-amino-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)-7-cyanobenzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;~~

(R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;

(S)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;

(R)-1-((7-cyano-2-(3'-(2-(hydroxymethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid;

(R)-1-((7-cyano-2-(3'-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-6-methyl-1,7-naphthyridin-8-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid; and

(R)-1-((7-cyano-2-(3'-(6-(difluoromethyl)-3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid,
or a pharmaceutically acceptable salt or a stereoisomer thereof.

373. A pharmaceutical composition comprising a compound of any one of claims 1-36, or a pharmaceutically acceptable salt or a stereoisomer thereof, and a pharmaceutically acceptable excipient or carrier.

4. A pharmaceutical composition comprising a compound of claim 2, and a pharmaceutically acceptable excipient or carrier.

38.—A method of inhibiting PD-1/PD-L1 interaction, said method comprising administering to a patient a compound of any one of claims 1-36, or a pharmaceutically acceptable salt or a stereoisomer thereof.

39.—A method of treating a disease or disorder associated with inhibition of PD-1/PD-L1 interaction, said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of any one of claims 1-36, or a pharmaceutically acceptable salt or a stereoisomer thereof.

40.—~~The method of claim 39, wherein the disease or disorder is an infection disease, inflammation, autoimmune disease, cancer, or neurodegenerative disorder~~

~~41. — A method of enhancing, stimulating and/or increasing the immune response in a patient, said method comprising administering to the patient in need thereof a therapeutically effective amount of a compound of any one of claims 1-36, or a pharmaceutically acceptable salt or a stereoisomer thereof.~~

5

5. A compound, which is (R)-1-((7-cyano-2-(3' -(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2' -dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

10

6. The compound of claim 5, which is (R)-1-((7-cyano-2-(3' -(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2' -dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid.

15

7. A pharmaceutical composition comprising a compound of claim 5, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

20

8. A pharmaceutical composition comprising a compound of claim 6 and a pharmaceutically acceptable excipient or carrier.

25

9. A compound, which is (R)-1-((7-cyano-2-(3' -(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2' -dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

30

10. The compound of claim 9, which is (R)-1-((7-cyano-2-(3' -(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2' -dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid.

11. A pharmaceutical composition comprising a compound of claim 9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

12. A pharmaceutical composition comprising a compound of claim 10 and a pharmaceutically acceptable excipient or carrier.

13. A compound, which is (R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

14. The compound of claim 13, which is (R)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid.

15. A pharmaceutical composition comprising a compound of claim 13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

16. A pharmaceutical composition comprising a compound of claim 14 and a pharmaceutically acceptable excipient or carrier.

17. A compound, which is (S)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

18. The compound of claim 17, which is (S)-1-((7-cyano-2-(3'-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2'-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid.

19. A pharmaceutical composition comprising a compound of claim 17, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

5 20. A pharmaceutical composition comprising a compound of claim 18 and a pharmaceutically acceptable excipient or carrier.